Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence
ReviewHumans
- Design
- Review
- Subjects
- 13 studies: 11 in people and 2 in animals
- Dose used in the study
- The supplementation studies used 600 mg once or twice a day for 8 to 12 weeks
- What was measured
- Levels of palmitoylethanolamide in people with psychosis, and the effects of supplementation
What the authors reported
The authors reported that six observational studies found raised plasma levels of palmitoylethanolamide in people with psychosis, which they describe as a possible early compensatory response. Three studies of supplementation reported reduced negative psychotic and manic symptoms, with no serious adverse events. The two animal models showed no change in palmitoylethanolamide.
Limits of this study
A systematic review without a pooled analysis. Only three of the studies tested supplementation. The authors' stated limitations, funding and conflict statements were not visible on the page checked.
Source
doi:10.3389/fpsyt.2023.1231710
Entry checked against the full text at the publisher (Frontiers) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.